Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marc de Garidel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 80
- Beta
- -0.25
- Country
- FR
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 40.59
Financials
Revenue
$0.00-100.0%Net Income
$-117.43MEBITDA
$-122.40MFree Cash Flow
$-52.10MEPS (diluted)
$-1.47Shares Outstanding (diluted)
79.65M+759.0%Operating Expenses
$85.31MCash & Debt
$410.68MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-336.10M | $-4.65 |
| 2024 | $0.00 | $-176.24M | $-2.80 |
| 2023 | $0.00 | $-147.74M | $-3.43 |
| 2022 | $0.00 | $-60.74M | $-3.18 |
| 2021 | $0.00 | $-42.45M | $-2.75 |
| 2020 | $63.0K | $-37.55M | $-2.62 |
| 2019 | $2.0K | $-30.63M | $-2.51 |
| 2018 | $18.0K | $-15.82M | $-1.56 |
| 2017 | $10.0K | $-11.22M | $-1.14 |
| 2016 | $127.0K | $-14.31M | $-1.48 |
| 2015 | $42.0K | $-15.95M | $-1.65 |
| 2014 | $14.0K | $-5.08M | $-0.73 |
| 2013 | $73.9K | $-5.89M | $-0.64 |
Valuation
ABVXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-13.04%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·30d ago·Neutral
Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts Abivax Société Anonyme is advancing obefazimod for ulcerative colitis and Crohn's, with recent safety concerns now largely addressed. ABVX raised $920 million, extending its cash runway into Q4 2029 and strengthening its negotiating position for potential M&A. ABVX stock is fairly valued in the $90s, with upside contingent on a favorable UC label and positive Phase 2b CD data in 2027.
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
…l position and flexibility to support future commercialization efforts PARIS, France – September 21, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, reported today business updates and financial results for the six months e…
View source ↗ - Newszacks.com·35d ago·Negative
4 Biotech Stocks to Watch as Potential Takeover Targets Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
View source ↗ - Newsbenzinga.com·39d ago·Negative
Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ABIVAX Société Anonyme (NASDAQ:ABVX) will release its first-half earnings report after the closing bell on Monday, Sept. 21.
View source ↗ - Newszacks.com·45d ago·Positive
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why Abivax SA Sponsored ADR (ABVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗
Earnings
Mon, Dec 21(in 8 weeks)
Consensus estimate $-0.92 per share
Typical surprise -5.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Sep 21$-1.71 vs $-0.98miss
- Fri, May 22$-0.71 vs $-1.07beat
- Mon, Mar 23$-1.19 vs $-1.70beat
- Mon, Dec 15$-2.47 vs $-0.79miss
- Mon, Sep 8$-0.86 vs $-0.90beat
- Mon, Jun 2$-0.97 vs $-0.76miss
Estimates and results for ABVX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in ABVX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.